•Design and development of manual immunoassays following Design Control requirements.•Managing scientists and establishing their individual goals to meet business unit objectives.•Publishing, patenting and presenting scientific findings.•Design, development and successfully commercialization of the following products ahead of schedule:cPAPP-A (circulating pregnancy associated plasma protein-A) ELISA for research use in cardiovascular disease. FDA audit completed with no findings.Inhibin-B Gen II ELISA for application in reproductive endocrinology and ovarian cancer (RUO and CE). ISO and corporate audits completed with no findings.AMH Gen II (Anti-Müllerian Hormone) ELISA for application in ovarian assessment (RUO and CE). Audited by corporate auditors.Total Inhibin ELISA assay for research use in ovarian cancer.Developed Activin A assay for research use in reproductive endocrinology•Functioned as manufacturing support lead for made to order products: •Functioned as technical operation support lead for resolution of performance and customer related issues.

Responsible for developing and commercializing new products following Design Control requirements •Assessing technical and financial feasibility of new diagnostic assay and technologies•Liaison with collaborators undertaking clinical trials•Providing scientific advice to technical services•Investigating new business opportunity for DSLDesigned, developed and successfully commercialized the following products ahead of schedule:•Micotiter plate based ActiveGlo™ chemiluminiscence technology. The complete solution to this glow technology was developed by my group. ActiveGlo™ luminometer, ActiveGlo™ data reduction software and the substrates were developed verified and validated.•ActiveGlo™ Dried Blood Spot (DBS) assays for Intact hCG and PAPP-A for use in first trimester screening tests. These products were developed on an automated liquid handling system (DSX) using a chemiluminescence technology. •Infectious Disease ELISAs (H. Pylori IgG, H. Pylori IgA, Treponema Pallidum IgG, Toxoplasma gondii IgG & IgM, Rubella IgG & IgM, Cytomegalovirus IgG, Herpes Simplex-I IgG, Herpes Simplex-II IgG Measles IgG, Mumps IgG, Varicella-Zoster IgG and Epstein Barr VCA IgG).

Polytechnic University •Senior Research Scientist at National Science Foundation center for Biocatalysis and Bioprocessing of Macromolecules. This NSF Center had seven Industrial Members Cargill-Dow, BASF, Novozymes, Maxygen, EcoSynthetix, Nalco, DSM working together to evolve the way industry must look towards renewable resources and biological processes for future polymer and materials needs. •Developed novel methods to incorporate polyols/other hydrophilic groups into polyester backbone. •Used biotransformation to prepare functional monomers, copolymers. •Enzyme catalyzed ring opening polymerization.•Studied enzyme kinetics and engineering control •Studied the effect of Immobilization of enzyme on various resin (solid support) •Compared enzyme catalysis to chemical catalyzed polymerization of lactones, carbonates and vinyl monomers.